RA
ASTX

Royce & Associates’s ASTEX PHARMACEUTICALS, INC COM ASTX Stock Holding History

Royce & Associates’s Portfolio ASTX Stock Details ASTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-12,300
Closed -$51K – 1502
2013
Q2 		$51K Buy
+12,300
New +$66.1K ﹤0.01% 1381

Other funds holding ASTX

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
SAM
Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return

Royce & Associates's ASTX Position: Q3 2013 in Review

Royce & Associates sold out of ASTEX PHARMACEUTICALS, INC COM (ASTX) in Q3 2013, closing a stake of 12,300 shares — an estimated $51K sold.

Royce & Associates first reported a position in ASTX in Q2 2013 and held it in 1 quarter. The position peaked at $51K in Q2 2013. 123 funds tracked by Wall St. Rank hold ASTX as of Q3 2013.

  • Royce & Associates reported no remaining ASTEX PHARMACEUTICALS, INC COM position as of Q3 2013 after selling out during the quarter.
  • Royce & Associates sold 12,300 ASTEX PHARMACEUTICALS, INC COM shares in Q3 2013, an estimated $51K.
  • Royce & Associates first reported a position in ASTEX PHARMACEUTICALS, INC COM in Q2 2013 and held it in 1 quarter.
  • Royce & Associates's ASTEX PHARMACEUTICALS, INC COM position peaked at $51K in Q2 2013.
  • 123 funds tracked by Wall St. Rank held ASTEX PHARMACEUTICALS, INC COM as of Q3 2013.

Based on Royce & Associates's 13F filing for Q3 2013, filed 12 Nov 2013.